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Drugs that activate opioid receptors are known to suppress bladder activity (2, 8, 11, (15) (16) (17) (18) 25) . For example, tramadol, an opioid receptor agonist and a serotonin and noradrenaline reuptake inhibitor, is effective in inhibiting normal and overactive bladders in rats (15) (16) (17) (18) . In normal human subjects, tramadol at the recommended analgesic dosage (150 mg daily) can cause urinary retention (11) . It is also effective in treating OAB symptoms at a slightly higher dosage (200 mg daily), which elicits significant adverse effects including nausea, vomiting, dizziness, and constipation (6, 25) .
In the present study, which was conducted on acetic acid (AA)-irritated bladders in cats, we determined if activation of opioid receptors with a low dosage of tramadol, which should have fewer adverse effects, enhances the inhibitory effect of TNS on reflex bladder activity. Our results show that a combination of TNS with a low dose of tramadol completely suppressed irritation-induced bladder overactivity, raising the possibility of a new treatment strategy for OAB.
MATERIALS AND METHODS
The Animal Care and Use Committee of the University of Pittsburgh approved all protocols involving the use of animals in this study.
Animal preparation. Experiments were conducted on 17 adult cats (8 males and 9 females, weight: 2.4 -4.0 kg) under ␣-chloralose anesthesia (65 mg/kg iv). The right carotid artery and ulnar vein were catheterized to monitor blood pressure and administer tramadol, respectively. Heart rate and blood oxygen level were monitored by a pulse oximeter (9847 V, NONIN Medical, Playmouth, MN) with the sensor attached to the tongue. Reduction of the blood oxygen level to ϳ85-90% was observed at high doses of tramadol (7-10 mg/kg iv), but artificial respiration was never used in this study. The ureters were cut and drained externally. A double lumen catheter was inserted through the urethra into the bladder and secured by a ligature around the urethra. One lumen of the catheter was connected to a pump to infuse the bladder with saline or 0.25% AA at a rate of 1-2 ml/min, and the other lumen was connected to a pressure transducer to measure intravesical pressure. A tripolar cuff electrode (NC223pt, MicroProbe, Gaithersburg, MD) was implanted on the left tibial nerve above the ankle.
Stimulation protocol and tramadol administration. Uniphasic rectangular pulses (0.2-ms pulse width) at 5-Hz frequency were delivered to the tibial nerve via the cuff electrode. The intensity threshold (T) for inducing toe movement was determined by gradually increasing the stimulation intensity. Because our previous study (31) indicated that a stimulus intensity of Ͼ2 T was required to inhibit reflex bladder contractions, intensities of 2 or 4 T were used to suppress bladder overactivity induced by 0.25% AA.
In 11 cats, TNS was applied during repeated cystometrograms (CMGs), which consisted of a slow infusion of AA starting with an empty bladder. Bladder capacity is defined as the threshold bladder volume to induce the first large-amplitude (Ͼ30 cmH 2O), longduration (Ͼ30 s) bladder contraction during a CMG (see the first trace in Fig. 1A) . Initially, three to five saline CMGs were performed without TNS to obtain the control bladder capacity and evaluate reproducibility. Another three to five CMGs were then performed during a 30-to 50-min period with an infusion of 0.25% AA to irritate the bladder, activate nociceptive bladder C-fiber afferents, and induce bladder overactivity. After bladder capacity stabilized, four CMGs were performed during AA infusion: 1) control without TNS, 2) during 2-T TNS, 3) during 4-T TNS, and 4) control without TNS (Fig.  1A) . Cumulative doses (0.3, 1, 3, and 7 mg/kg iv) of tramadol (Sigma-Aldrich, St. Louis, MO) were then given. Starting 10 min after each dose of tramadol, the four CMGs were repeated during AA infusion. A 5-min rest period was inserted between each CMG to allow for recovery of the micturition reflex. At the end of the experiments (n ϭ 9), a higher dose of tramadol (10 mg/kg iv) was given to examine the maximal inhibitory effect. Naloxone (2 mg/kg iv) was then used to maximally antagonize opioid receptors and to determine if the inhibitory effect induced by combination of TNS and tramadol treatment could be reduced.
In another six cats, a similar protocol was used except that after AA irritation of the bladder, saline vehicle was administered intravenously instead of tramadol between each group of four CMGs to evaluate the effect of repeated TNS on bladder capacity. This was followed by a series of CMGs without TNS during which cumulative doses (0.3, 1, 3, and 7 mg/kg) of tramadol were administered to examine the effect of the drug alone on bladder capacity. After administration of the largest dose of tramadol, the four CMG protocol was repeated, followed by an additional five CMGs without stimulation to determine if a poststimulation inhibition was unmasked by tramadol.
Data analysis. Bladder capacity was measured during each CMG and normalized to the first saline control CMG in each experiment. However, when poststimulation inhibition was evaluated, the bladder capacities measured during the last five CMGs after TNS were normalized to the control CMG performed after 7 mg/kg tramadol. Repeated measurements in the same animal during the same experiment were averaged. Normalized data from different animals are presented as means Ϯ SE. ANOVA followed by Dunnett's multiplecomparison test and Student's t-test were used to detect statistical significance (P Ͻ 0.05).
RESULTS

Tibial nerve inhibition of bladder overactivity induced by AA irritation.
Bladder capacities during saline CMGs averaged 9.9 Ϯ 1.1 ml (n ϭ 17 cats). The subsequent infusion of 0.25% AA significantly (P Ͻ 0.0001) reduced bladder capacity to 24.8 Ϯ 3.3% of the control capacity (Fig. 1) . During AA infusion, bladder capacity remained constant during repeated CMGs (bladder capacity ϭ 26.7 Ϯ 5.9% of control at the end of 2.5-3 h; Fig. 2C ).
TNS (5 Hz) at 2 or 4 T applied during AA CMGs significantly (P Ͻ 0.01, n ϭ 17 cats) increased bladder capacity to 46.7 Ϯ 4.9% and 62.6 Ϯ 6.2%, respectively, of the saline control capacity ( Fig. 1 ) but failed to completely reverse the effect of AA irritation. Bladder capacity returned to the control level within 5 min after the termination of TNS (see last trace and bar in Fig. 1 , A and B). Repeated application of TNS at 2 and 4 T during AA infusion CMGs for five times during a period of 2.5-3 h (n ϭ 6 cats) elicited reversible ( Fig. 2C ) and reproducible increases in bladder capacity (50 -60%).
Dose-dependent effect of tramadol on bladder overactivity. The effect of tramadol alone on AA-irritated bladders in the absence of TNS was examined in six cats by administering increasing doses of the drug at 20-min intervals to construct cumulative dose-response curves (see "no stimulation" curve in Fig. 3 ). Bladder capacity was not significantly changed at the 0.3 and 1 mg/kg doses, whereas the 3 and 7 mg/kg doses significantly (P Ͻ 0.01) reversed the irritant effect of AA, increasing bladder capacity to 50% and 60%, respectively, of the saline control capacity (see no stimulation curve in Fig. 3 ). The effects of the two largest doses were not significantly different.
Effect of combined TNS and tramadol treatment on bladder overactivity. The combined effect of tramadol and TNS was examined by administering increasing cumulative drug doses and then testing TNS at 2 and 4 T after each dose. As the tramadol dose increased above 0.3 mg/kg, bladder capacities 4A ) progressively increased. After 3 mg/kg tramadol, bladder capacity was significantly (P Ͻ 0.05) larger than control capacity, and after 7 mg/kg, bladder capacity was fully restored to the saline control level (before stimulation curve, Fig. 3 ). Although these changes in bladder capacity were larger than those induced when tramadol was administered alone in the absence of TNS (compare before stimulation curve with no stimulation curve in Fig. 3 ), the differences were not statistically significant (P ϭ 0.29).
TNS (2 and 4 T) applied after the administration of each tramadol dose significantly (P Ͻ 0.05) increased bladder capacity (Figs. 3 and 4 , B and C). After 3 mg/kg tramadol, TNS at 2 and 4 T completely reversed the effect of AA irritation (Fig. 3) . TNS after 7 mg/kg tramadol increased bladder capacity to 140 -150% of the saline control (Figs. 3 and 4) . The combined effect of TNS and tramadol at 3-7 mg/kg doses was significantly (P Ͻ 0.05) larger than the effect of TNS alone or the combined effect of the lowest dose (0.3 mg/kg) of tramadol and TNS (Fig. 3) .
Poststimulation inhibition of bladder overactivity emerged after tramadol treatment. The increase in bladder capacity induced by TNS during AA CMGs rapidly (within 5 min) and completely reversed after termination of the stimulation (Figs.  1A and 2C ). This rapid reversal contrasted with the prolonged increase in bladder capacity (i.e., poststimulation inhibition) that persists for at least 2 h after termination of TNS during saline CMGs (31) . To determine if tramadol unmasks poststimulation inhibition in AA-irritated bladders, we examined the recovery of bladder capacity after TNS after a range of tramadol doses (Fig. 2B) . Low doses of tramadol (0.3 and 1 mg/kg) did not generate a poststimulation inhibition; however, 3 mg/kg (Fig. 2, A and B) and 7 mg/kg (Figs. 2B and 5) unmasked a significant poststimulation increase in bladder capacity. After 7 mg/kg tramadol, this increase persisted during a series of five subsequent CMGs for a period of at least 1.5-2 h (Fig. 5) .
Effect of naloxone on combined TNS and tramadol treatment. At the end of the experiments, a higher dose (10 mg/kg) of tramadol was administered, which eliminated the micturition reflex in six of nine cats (Fig. 6A) . Naloxone (2 mg/kg iv) restored the micturition reflex (Fig. 6A ) and significantly reduced bladder capacity to Ͻ1 ml (Fig. 6B) . After naloxone treatment, TNS did not inhibit bladder activity even at a stimulation intensity of 8 T (Fig. 6C) .
DISCUSSION
This preclinical study revealed that TNS alone inhibits AA-induced bladder overactivity, but its efficacy was low (50 -60% increase in bladder capacity; Fig. 1 ). Tramadol without TNS also produced an incomplete reversal of AAinduced bladder overactivity, similar to that produced by TNS. However, TNS in combination with tramadol (Ն3 mg/kg) normalized the capacity of the irritated bladder (Figs. 3 and 4) . Tramadol (3-7 mg/kg) also unmasked a post-TNS inhibition (Figs. 2 and 5 ) that normalized bladder capacity for a period of at least 1.5-2 h after the stimulation (Fig. 5) . These results raise the possibility that neuromodulation in combination with tramadol might be an effective new strategy for treating OAB.
Tramadol is known to produce a number of adverse effects, including nausea, vomiting, dizziness, and constipation (6, 25) , which prevent the use of higher doses to achieve greater clinical efficacy. Thus, the dose of tramadol necessary to enhance TNS effects in cats is an important consideration in evaluating the clinical implications of the present results. However, relating the tramadol doses in cats to doses in humans is complicated due to species differences and different routes of administration. When tramadol is used clinically as an analgesic, the recommended oral dose is 50 -100 mg every 4 -6 h, with a maximum dose of 400 mg/day (6) . A recent study (25) has shown that tramadol (100 mg or 1.4 mg/kg for a 70-kg person twice per day) significantly reduced the number of incontinence episodes and produced a 25% increase in bladder capacity in OAB patients. Thus, the human dose is approximately half of the intravenous dose of tramadol (Ն3 mg/kg) that increased bladder capacity and facilitated TNS in our present study and less than half of the recommended oral dose (4 mg/kg every 6 h) to treat pain in cats (20, 21) . These data indicate that cats are less sensitive to the effects of tramadol. Although our experiments examined the effects of tramadol administered intravenously, this is not likely to be a major impediment to predicting clinical efficacy because oral tramadol is rapidly and almost completely absorbed in cats and intravenous and oral doses of tramadol produce similar plasma concentrations (20) . Thus, it seems reasonable to conclude that oral doses of tramadol that produce analgesia in the cat should also be effective in facilitating TNS inhibition of bladder overactivity in the cat. If these data and conclusions are applicable to humans, then analgesic doses of tramadol should also enhance TNS suppression of OAB symptoms.
Tramadol is a complex drug that potentially acts at many sites in the central nervous system and via multiple mechanisms of action (22, 23) . Tramadol and its active metabolite are -opioid receptor agonists. Tramadol also inhibits reuptake of serotonin and norepinephrine at presynaptic terminals and elicits effects by indirectly activating serotonergic and ␣ 2 -adrenergic receptors (6, 22, 23) . In the cat, the respiratory depression elicited by tramadol (1-4 mg/kg administered intravenously) is significantly reduced by treatment with naloxone, indicating that this effect is dependent on the activation of opioid receptors (32) . Reflex bladder activity in the cat is under tonic enkephalinergic inhibitory control mediated by -and ␦-opioid receptors in the brain and spinal cord, respectively (2, 8, 14, 24) . Block of these receptors with naloxone, an opioid receptor antagonist, reduces bladder capacity and induces bladder overactivity in the anesthetized cat (2, 14) . Naloxone also suppresses the inhibition of reflex bladder activity induced by TNS (29) or pudendal nerve stimulation (3), indicating an important role of endogenous opioid peptides and opioid receptors in the neuromodulation of bladder function in cats. Our present result (Fig. 6 ) further showed that naloxone reverses the inhibition of bladder overactivity induced by the combined treatment of tramadol and TNS. These data raise the possibility that the inhibitory effect of tramadol alone on bladder overactivity and the facilitation of the TNS inhibition by tramadol are due to actions at enkephalinergic inhibitory synapses in the brain or spinal cord.
An inhibitory action of tramadol on serotononin and norepinephrine reuptake mechanisms is also a possible contributor to the actions of tramadol on bladder overactivity because naloxone resistant analgesia induced by tramadol has been demonstrated in rodents (22, 23) and some of the naloxone-resistant effects of tramadol on neural pathways in the brain are blocked by ␣ 2 -adrenergic receptor antagonists or modified by inhibitors of serotonin synthesis (26, 36) . Serotonin-norepinephrine reuptake inhibitors (e.g., duloxetine) (33) and serotonergic receptor agonists (7, 30, 34) have prominent inhibitory effects on bladder overactivity in anesthetized cats, indicating a role of endogenous monoamines in the control of the bladder as well as a possible role of these neurotransmitters in the actions of tramadol on bladder reflexes.
The interactions between tramadol and TNS can be separated into two components: 1) enhancement of the transient TNS inhibition by tramadol, which might simply reflect the summation of the two independent inhibitory effects; and 2) the unmasking of TNS poststimulation inhibition. The latter interaction could be defined as potentiation because the effect of the combined treatment is greater than the algebraic summation of the individual treatments.
The failure of TNS to elicit poststimulation inhibition in the AA irritation model before tramadol treatment was unexpected because our previous study (31) in nonirritated bladders in cats showed a TNS poststimulation inhibition of reflex bladder activity that persisted for at least 2 h. Thus, AA irritation may activate a nociceptive mechanism that suppresses the synaptic changes underlying the prolonged TNS poststimulation inhibition. Tramadol that has analgesic properties may block this nociceptive mechanism and unmask the prolonged inhibition.
Another explanation for the absence of TNS poststimulation during AA-irritated CMG is that bladder activity in irritated and nonirritated bladders may depend on different reflex pathways. Bladder distention by saline infusion primarily activates nonnociceptive bladder A␦-afferent fibers, which induce a supraspinal micturition reflex, whereas AA irritation of the bladder also activates nociceptive bladder C-fiber afferents, which trigger a spinal micturition reflex (4, 5) . Therefore, our failure to demonstrate a poststimulation inhibition of the AAirritated cat bladder suggests that the long-lasting effects of tibial neuromodulation on OAB symptoms in humans might be related to inhibition of the A␦-fiber-mediated supraspinal micturition pathway and that TNS induced poststimulation inhibition of C-fiber-mediated bladder overactivity can only be induced by TNS when combined with tramadol treatment.
If our results in cats showing additive effects of tramadol and TNS (Fig. 3) translate to humans, then the clinical dosage of tramadol necessary for treating OAB could be significantly reduced when combined with tibial neuromodulation, thereby significantly reducing or eliminating the adverse effects of tramadol. The proposed combined new treatment strategy also provides significant advantages over sacral or tibial neuromodulation alone because sacral neuromodulation, which has a high efficacy in OAB treatment, is invasive, requiring surgery to implant the stimulator and electrode (13, 35) . Tibial neuromodulation is minimally invasive, only requiring insertion of a needle electrode at the ankle to stimulate the tibial nerve, but its efficacy is lower than sacral neuromodulation (10, 19) . Our results (Figs. 3 and 4) showed that the efficacy of tibial neuromodulation can be significantly increased to completely inhibit bladder overactivity if combined with a low dose of tramadol, potentially yielding a treatment strategy that would be minimally invasive with a high efficacy and fewer adverse effects.
Clinical tibial neuromodulation requires a 30-min treatment once per week for 12 wk followed by maintenance treatments once every 2-3 wk (10, 19) , indicating a significant poststimulation inhibitory effect. Our present results (Figs. 2 and 5) showing that tramadol unmasks and/or enhances the TNS poststimulation inhibition in a bladder overactivity model raise the possibility that the clinical use of a combined treatment strategy might reduce the number of treatments required to produce a clinical response and increase the interval between maintenance treatments as well as the maximum efficacy of TNS by expanding the number of central pathways sensitive to neuromodulation. Since tibial neuromodulation and tramadol are both used in clinical practice, a clinical trial to test the combined treatment and to determine the duration of tramadol induced poststimulation inhibition should be feasible.
In summary, this study suggests a novel treatment strategy for OAB by combining tibial neuromodulation with a low dose of tramadol. This strategy is minimally invasive with a potentially high efficacy and fewer adverse effects. If this combined pharmacological-neuromodulation therapy is proven to be successful in clinical trials, it could have a significant impact on the treatment of OAB.
GRANTS
This work was supported by National Institute of Diabetes and Digestive and Kidney Diseases Grants DK-068566, DK-090006, and DK-091253.
DISCLOSURES
No conflicts of interest, financial or otherwise, are declared by the author(s). 
AUTHOR CONTRIBUTIONS
